5‐FU/cisplatin/anthracycline combinations vs 5‐FU/cisplatin combinations (without anthracyclines)
Time to progression · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations may leads to lower time to progression compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
1 finding from 1 review
- HR 0.62 [0.38, 0.98]1 study · 78 participantsLow